
Napigen Inc Profile last edited on: 10/20/2024
CAGE: 7QU54
UEI: KJD2HMU4QDK5
Business Identifier: Novel genome engineering of various organisms: plants, microbes and animals Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 00
County: New Castle
Congr. District: 00
County: New Castle
Public Profile
Specialists in mitochondrial engineering, Napigen is a biotechnology, genome editing company addressing the what could be the unmet needs of future food supplies by creating hybrid crop plants with boosted yields. The companys technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elite backgrounds - allowing production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid: example: wheat. Addressing novel genome engineering of various organisms - plants, microbes and animals - NAPIGEN is targeting two special cellular components known as organelles that harbor their own DNA: mitochondria and chloroplasts. With both organelles important to the creation of energy for cells to grow, both are also critical for producing various biochemical molecules that key to specific pathways and functions. Applications of the firm's genome technology range from industrial biotechnology to animal and human healthcare and also agriculture.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 1 | NIH | $225,000 | |
Project Title: New Transformation Technology for Gene Editing of Human Mitochondrial DNA Associated With Mitochondrial Diseases | ||||
2020 | 1 | USDA | $100,000 | |
Project Title: Development of mitochondrial transformation in plants toward creating elite hybrid wheat | ||||
0 | 1 | USDA | $175,000 | |
Project Title: Development of a herbicide resistance trait incapable of pollen transmission to weed plants |
Key People / Management
Hajime Sakai -- CEO, Co-Founder, Founder, President
Michael Gillespie -- Board Member RA Capital
Jay Keasling -- Co-Founder, Chairman of the Scientific Advisory Board JBEI CEO, UC Berkley
Ganesh Kishore -- Co-Founder & Board Member
Nandini Krishnamurthy -- Former Board Member
Hemai Parthasarathy -- Former Board Observer the Breakout Labs
Roger Wyse -- Co-Founder & Board Member
Michael Gillespie -- Board Member RA Capital
Jay Keasling -- Co-Founder, Chairman of the Scientific Advisory Board JBEI CEO, UC Berkley
Ganesh Kishore -- Co-Founder & Board Member
Nandini Krishnamurthy -- Former Board Member
Hemai Parthasarathy -- Former Board Observer the Breakout Labs
Roger Wyse -- Co-Founder & Board Member
Company News
There are no news available.